Merrill updates Bio-Stats

Merrill Lynch analyst Eric Ende summarized recent activity in the biotechnology market, noting that pipeline supply remains at an all-time high of $9.1 billion, with $1.1 billion of deals priced in March. The four-week moving average funds flow is plus $56 million, compared with the prior month's average of minus $63 million. March saw $1.1 billion of new supply come into the market, but February saw $5.6 billion. For March, the ML Therapeutic index decreased 2.6% and the ML Genomics/ Tools Index was flat. The ML Small-Cap Biotech Index decreased 0.6%; the ML Mid-Cap Biotech Index was down 4.5% and the ML Large-Cap Biotech Index was down 2.0%.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.